In vitro immuno-oncology models are used to study the interaction of therapeutics with immune cells in a 2D or 3D assay format. These models are used to assess the effect of compounds and therapeutic antibodies on immune cell infiltration or to screen immune cell populations for use in immunotherapy. The 3D cell culture models are more biologically relevant and allow for proper assessment of immunotherapies designed to promote the immune cell response to tumor cells. Visikol’s in vitro immuno-oncology models and high content imaging technology can address limitations by providing a method for improving in vitro studies used in drug discovery and development. In this blog post, we will explore how Visikol’s in vitro immuno-oncology models can be used for high content imaging, allowing for more accurate and reliable data for drug efficacy and safety testing. We will also discuss how Visikol’s 3D cell culture models are more biologically relevant and how their high content imaging technology can help researchers and pharmaceutical companies maximize the potential of their immuno-oncology models.

More on High Content Imaging

High content imaging technology is a method of in vitro assay services that allows for the assessment of multiple endpoints simultaneously at a cellular resolution. It utilizes imaging-based endpoints to examine the specific effect of compound treatments on specific sub-populations of cells, as well as providing access to more complex measurements than can be accomplished with traditional assay formats. The data generated from high content imaging is processed using purpose-built image processing pipelines to obtain quantitative data, extracting cell counts, morphological features, colocalization of labels, and computing statistical comparisons between groups simultaneously.

High content imaging technology allows for the assessment of multiple endpoints simultaneously at a cellular resolution, providing richer datasets than traditional assays. This approach enables the interrogation and quantitation of cellular response of disease models to treatments, stimuli, or alterations in protein expression. The use of imaging-based endpoints allows for examination of the specific effect of compound treatments on specific sub-populations of cells, as well as providing access to more complex measurements than can be accomplished with traditional assay formats. Combining these data with machine-learning and informatics expertise, comprehensive reports can be generated that distill the data to its essential components, giving actionable insights about the experiment.

Visikol’s in vitro Immuno-Oncology Models

Visikol’s in vitro immuno-oncology models and high content imaging technology can address limitations by providing a method for improving in vitro studies used in drug discovery and development. They offer tissue analysis services for immuno-oncology research, which aims to understand how the immune system interacts with the tumor microenvironment and modulate the immune response to reduce tumor growth. They employ multiplex immunofluorescence to simultaneously interrogate multiple cell populations and use automated image processing algorithms to assess the variety and distribution of immune cells within and around tumor tissue. They also offer High Content Screening services to clients utilizing 3D cell models and traditional cell-based assays. They provide a wide range of validated in vitro screening services, rapid custom assay development, and end-to-end compound screening services.

3D Cell Culture Models

3D cell culture models are a method of growing cells that better replicates the complex characteristics of the in vivo microenvironment, such as diffusion gradients and receptor expression. Traditional 2D cell culture is limited in its ability to replicate these characteristics. The technique in which cells are cultured (2D vs. 3D) can substantially alter the drug’s effect on the cells. 3D cell culture models offer a more natural, tissue-mimicking method of cell growth for drug discovery applications.

Visikol’s expertise in 3D cell culture models and high content imaging technology allows for the assessment of multiple endpoints simultaneously at a cellular resolution. This provides richer datasets than traditional assays, enabling the interrogation and quantitation of cellular response of disease models to treatments, stimuli, or alterations in protein expression. The use of imaging-based endpoints allows for examination of the specific effect of compound treatments on specific sub-populations of cells, as well as providing access to more complex measurements than can be accomplished with traditional assay formats.

Visikol’s in vitro immuno-oncology models and high content imaging technology can provide a method for improving in vitro studies used in drug discovery and development. Their 3D cell culture models are more biologically relevant and allow for a proper assessment of immunotherapies designed to promote the immune cell response to tumor cells. Their high content imaging technology can help researchers and pharmaceutical companies maximize the potential of their immuno-oncology models by providing a method for assessing multiple endpoints simultaneously at a cellular resolution. By utilizing these technologies, researchers can obtain more accurate and reliable data for drug efficacy and safety testing, ultimately leading to the development of more effective cancer treatments.

If you’re interested in learning more, please reach out to a member of our team today!

Liver fibrosis is a serious condition that affects millions of people worldwide. It is a pathological overaccumulation of excess connective tissue resulting in scar formation, reduced organ function, and ultimately organ failure. The shift from appropriate wound healing to pathological fibrosis occurs as the rate of extracellular matrix deposition outstrips the rate of degradation. The causes of liver fibrosis can include chronic disease, autoimmune response, or long-term exposure to pollutants and toxins.

More on Liver Fibrosis

Symptoms of liver fibrosis may not be noticeable until the disease has progressed to cirrhosis. Diagnosis typically involves imaging tests, blood tests, and a liver biopsy. The prevalence of liver fibrosis is high, with nearly 45% of all deaths in the developed world attributed to chronic fibroproliferative diseases. It is more common in certain populations, such as those with chronic hepatitis B or C infections.

There are currently no approved treatments for liver fibrosis, but research is ongoing. In vitro models, such as the liver fibrosis assay offered by Visikol, are used to study the disease and potential treatments.

Visikol’s Liver Fibrosis Assay

In vitro models are an essential tool for researchers studying liver fibrosis. These models allow researchers to study the disease in a controlled environment, without the need for animal models or human subjects. In vitro models also allow researchers to evaluate multiple endpoints using a single sample, which can save time and resources.

One of the most significant advantages of in vitro models is the ability to use 3D cell culture models. These models incorporate a mixture of hepatocytes or hepatocyte-like cells with nonparenchymal cells (NPCs) to provide the greatest utility. 3D cell culture models offer a more accurate representation of the in vivo environment, allowing researchers to study the complex interactions between different cell types and the extracellular matrix that occur in vivo.

Visikol’s 3D cell culture models to study the disease and potential treatments. The assay analyzes gene expression via qPCR, allowing for many genes of interest to be evaluated using a single sample. The assay also offers basic and add-on endpoints, including qPCR, immunofluorescent labeling, ELISA, cytokine panels, plate reader cytotoxicity assay, and ATP assay. Dose response curves and EC50 values for select genes of interest in response to anti-fibrotic agents are provided.

The assay provides highly-validated assays with consistency and quality control processes that are available for liver models. In vitro compound screening, gene expression analysis, immunolabeling and confocal imaging of liver models, preparation and analysis of tissue sections from animal or human tissues, and advanced image processing and classification of clinical specimens using machine learning are offered. Custom drug discovery solutions are available for researchers who require a more customized approach to their drug discovery projects.

Liver fibrosis is a serious condition that affects millions of people worldwide. In vitro models, such as Visikol’s liver fibrosis assay, are an essential tool for researchers studying the disease and potential treatments. If you’re interested in learning more, please reach out to a member of our team today!